Cargando…
Systemic dendrimer-drug nanomedicines for long-term treatment of mild-moderate cerebral palsy in a rabbit model
BACKGROUND: Neuroinflammation mediated by microglia plays a central role in the pathogenesis of perinatal/neonatal brain injury, including cerebral palsy (CP). Therapeutics mitigating neuroinflammation potentially provide an effective strategy to slow the disease progression and rescue normal brain...
Autores principales: | Zhang, Zhi, Lin, Yi-An, Kim, Soo-Young, Su, Lilly, Liu, Jinhuan, Kannan, Rangaramanujam M., Kannan, Sujatha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586697/ https://www.ncbi.nlm.nih.gov/pubmed/33100217 http://dx.doi.org/10.1186/s12974-020-01984-1 |
Ejemplares similares
-
Nanomedicine in cerebral palsy
por: Balakrishnan, Bindu, et al.
Publicado: (2013) -
Dendrimer-Conjugated Glutamate Carboxypeptidase II Inhibitor Restores Microglial Changes in a Rabbit Model of Cerebral Palsy
por: Sah, Nirnath, et al.
Publicado: (2023) -
Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation
por: Zhang, Fan, et al.
Publicado: (2016) -
Preferential and Increased Uptake of Hydroxyl-Terminated PAMAM Dendrimers by Activated Microglia in Rabbit Brain Mixed Glial Culture
por: Alnasser, Yossef, et al.
Publicado: (2018) -
Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics
por: Sharma, Anjali, et al.
Publicado: (2018)